Tactics of antihypertensive therapy during COVID-19 pandemic

Results of foreign and Russian studies indicate a higher mortality rate of patients with concomitant cardiovascular diseases (CVD) due to the new coronavirus infection COVID-19. It has been proven that arterial hypertension, as one of the significant risk factors for the development of concomitant c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Valery I. Podzolkov, Anna Е. Bragina, Yulia N. Rodionova, Galina I. Bragina, Ekaterina E. Bykova
Formato:	article
Lenguaje:	RU
Publicado:	"Consilium Medicum" Publishing house 2021
Materias:	covid-19 cardiovascular diseases hypertension angiotensin-converting enzyme inhibitors lisinopril diuretics indapamide renin-angiotensin-aldosterone system Medicine R
Acceso en línea:	https://doaj.org/article/a39b4a68a3584c2ca850552d17dbde5a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a39b4a68a3584c2ca850552d17dbde5a
record_format	dspace
spelling	oai:doaj.org-article:a39b4a68a3584c2ca850552d17dbde5a2021-12-01T12:22:36ZTactics of antihypertensive therapy during COVID-19 pandemic0040-36602309-534210.26442/00403660.2021.09.201015https://doaj.org/article/a39b4a68a3584c2ca850552d17dbde5a2021-09-01T00:00:00Zhttps://ter-arkhiv.ru/0040-3660/article/viewFile/82986/63483https://doaj.org/toc/0040-3660https://doaj.org/toc/2309-5342Results of foreign and Russian studies indicate a higher mortality rate of patients with concomitant cardiovascular diseases (CVD) due to the new coronavirus infection COVID-19. It has been proven that arterial hypertension, as one of the significant risk factors for the development of concomitant cardiovascular diseases, is associated with a more severe prognosis of COVID-19. This article presents the results of modern studies and large meta-analyzes of necessity and safety of the use of blockers of the renin-angiotensin-aldosterone system in patients with arterial hypertension and COVID-19. The data of studies show that an angiotensin-converting enzyme inhibitor (ACE inhibitor) and a thiazide-like diuretic is a pathogenetically rational combination. It realizes various ways of lowering blood pressure by reducing the activity of the renin-angiotensin-aldosterone system, which is achieved by using an ACE inhibitor, and natriuresis due to diuretics. As an example, a highly effective fixed combination of drugs is considered, characterized by good tolerance, which consists of an ACE inhibitor lisinopril and a thiazide-like diuretic indapamide of prolonged action. The authors expressed the opinion that the appointment of the fixed combination drug Diroton Plus (Gedeon Richter) will contribute to effective control of blood pressure and organoprotection in conditions of increased thrombogenic and prooxidative potential, characteristic of COVID-19 both in the acute stage and within the post-COVID Syndrome.Valery I. PodzolkovAnna Е. BraginaYulia N. RodionovaGalina I. BraginaEkaterina E. Bykova"Consilium Medicum" Publishing housearticlecovid-19cardiovascular diseaseshypertensionangiotensin-converting enzyme inhibitorslisinoprildiureticsindapamiderenin-angiotensin-aldosterone systemMedicineRRUТерапевтический архив, Vol 93, Iss 9, Pp 1125-1131 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	covid-19 cardiovascular diseases hypertension angiotensin-converting enzyme inhibitors lisinopril diuretics indapamide renin-angiotensin-aldosterone system Medicine R
spellingShingle	covid-19 cardiovascular diseases hypertension angiotensin-converting enzyme inhibitors lisinopril diuretics indapamide renin-angiotensin-aldosterone system Medicine R Valery I. Podzolkov Anna Е. Bragina Yulia N. Rodionova Galina I. Bragina Ekaterina E. Bykova Tactics of antihypertensive therapy during COVID-19 pandemic
description	Results of foreign and Russian studies indicate a higher mortality rate of patients with concomitant cardiovascular diseases (CVD) due to the new coronavirus infection COVID-19. It has been proven that arterial hypertension, as one of the significant risk factors for the development of concomitant cardiovascular diseases, is associated with a more severe prognosis of COVID-19. This article presents the results of modern studies and large meta-analyzes of necessity and safety of the use of blockers of the renin-angiotensin-aldosterone system in patients with arterial hypertension and COVID-19. The data of studies show that an angiotensin-converting enzyme inhibitor (ACE inhibitor) and a thiazide-like diuretic is a pathogenetically rational combination. It realizes various ways of lowering blood pressure by reducing the activity of the renin-angiotensin-aldosterone system, which is achieved by using an ACE inhibitor, and natriuresis due to diuretics. As an example, a highly effective fixed combination of drugs is considered, characterized by good tolerance, which consists of an ACE inhibitor lisinopril and a thiazide-like diuretic indapamide of prolonged action. The authors expressed the opinion that the appointment of the fixed combination drug Diroton Plus (Gedeon Richter) will contribute to effective control of blood pressure and organoprotection in conditions of increased thrombogenic and prooxidative potential, characteristic of COVID-19 both in the acute stage and within the post-COVID Syndrome.
format	article
author	Valery I. Podzolkov Anna Е. Bragina Yulia N. Rodionova Galina I. Bragina Ekaterina E. Bykova
author_facet	Valery I. Podzolkov Anna Е. Bragina Yulia N. Rodionova Galina I. Bragina Ekaterina E. Bykova
author_sort	Valery I. Podzolkov
title	Tactics of antihypertensive therapy during COVID-19 pandemic
title_short	Tactics of antihypertensive therapy during COVID-19 pandemic
title_full	Tactics of antihypertensive therapy during COVID-19 pandemic
title_fullStr	Tactics of antihypertensive therapy during COVID-19 pandemic
title_full_unstemmed	Tactics of antihypertensive therapy during COVID-19 pandemic
title_sort	tactics of antihypertensive therapy during covid-19 pandemic
publisher	"Consilium Medicum" Publishing house
publishDate	2021
url	https://doaj.org/article/a39b4a68a3584c2ca850552d17dbde5a
work_keys_str_mv	AT valeryipodzolkov tacticsofantihypertensivetherapyduringcovid19pandemic AT annaebragina tacticsofantihypertensivetherapyduringcovid19pandemic AT yulianrodionova tacticsofantihypertensivetherapyduringcovid19pandemic AT galinaibragina tacticsofantihypertensivetherapyduringcovid19pandemic AT ekaterinaebykova tacticsofantihypertensivetherapyduringcovid19pandemic
_version_	1718405191552729088

Tactics of antihypertensive therapy during COVID-19 pandemic

Ejemplares similares